Filing summary
Registrant and period: The supplied filing is NLS Pharmaceutics Ltd.’s Form 20-F for the fiscal year ended December 31, 2021, filed March 24, 2022—not a standalone 2021 fourth-quarter report. This differs from the request metadata naming Newcelx Ltd.
Business context: NLS is a clinical-stage biopharmaceutical company developing mazindol extended-release candidates: Quilience for narcolepsy and Nolazol for ADHD. It had no approved products and no product-sales revenue. Financial statements are prepared under U.S. GAAP, with the U.S. dollar as reporting currency.
Financial results and position
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 recognized | $0 recognized |
| Research and development expense | $5.92 million | $0.10 million |
| General and administrative expense | $5.94 million | $2.20 million |
| Operating loss | $11.86 million | $2.30 million |
| Net loss | $11.95 million | $2.86 million |
| Basic and diluted loss per share | $1.00 | $0.41 |
| Net cash used in operating activities | $14.94 million | $0.73 million |
| Cash and cash equivalents at year-end | $5.43 million | $0.09 million |
- Research and development spending rose substantially as the company began the Quilience Phase 2 trial and incurred clinical manufacturing, NLS-4 preclinical and Novartis license costs. General and administrative expense increased with staffing, public-company, insurance, patent and investor-relations costs.
- Working capital at December 31, 2021 was approximately $3.32 million (current assets $5.72 million less current liabilities $2.40 million). Total assets were $5.76 million, total liabilities $5.22 million, and shareholders’ equity $0.54 million.
- The company reported an accumulated deficit of $41.71 million. It recognized no revenue; the $2.5 million Eurofarma upfront license payment remained deferred, pending completion of performance obligations and relevant regulatory approval.
- All outstanding loans and notes were repaid in February 2021; the balance sheet reported no loan or credit-facility balances at year-end. Deferred revenue and an accrued pension liability remained among non-current liabilities. Gross margin is not meaningful because there were no product sales.
- 2021 financing cash flow was $20.34 million, primarily from the IPO, warrant exercises and equity transactions, partly offset by debt repayments. Investing cash outflow was $39,560, mainly for furniture and software.
Changes, outlook and material risks
- Funding and runway: Year-end cash was $5.43 million. The filing describes potential funding through a standby equity distribution agreement (SEDA; up to $20 million under its terms, with shares priced at a discount) and a post-year-end ATM facility of up to $3.9 million. Management gives differing runway statements: cash expected to fund operations into Q2 2022 in one passage, but sufficient resources for more than 12 months from issuance of the financial statements in another; it also says additional liquidity may be needed to fund operations into Q1 2023. These are forecasts, not assured funding.
- Development: The company reported positive interim topline results in March 2022 for the ongoing Quilience narcolepsy Phase 2 trial: 27 participants were included in the interim analysis; the reported ESS decrease was 7.3 points on treatment versus 3.0 on placebo. No serious adverse events were reported in that interim group. Results were preliminary, based on a small subset of the target enrollment, and subject to further data collection and verification. A Phase 3 program was conditional on trial results, regulatory discussions and additional capital. Nolazol’s further ADHD development was on hold, although management said it might resume later.
- Key risks: The business depends on unapproved candidates and future financing, with no established product revenue. Clinical, regulatory and patient-enrollment outcomes are uncertain; COVID-19 may disrupt trials and operations. NLS relies on a sole mazindol supplier and third-party manufacturers, has no manufacturing facilities, and faces controlled-substance, reimbursement, competition and intellectual-property risks.
- Controls and other matters: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end because of weaknesses in U.S. GAAP expertise and segregation of duties. Remediation was ongoing; the auditor did not provide an internal-control attestation because of the emerging-growth-company exemption. No material legal proceedings were reported. The company had no dividend history and did not expect to pay dividends in the foreseeable future.
- Audit: PricewaterhouseCoopers AG gave an unqualified opinion on the financial statements.
Most important facts to verify
- Confirm the registrant and period: this is NLS Pharmaceutics Ltd.’s annual report for the year ended December 31, 2021, not a Newcelx filing or a standalone Q4 report.
- Reconcile management’s differing cash-runway statements and verify the actual availability, pricing, capacity and dilution implications of SEDA and ATM funding.
- Review the complete audited statements and notes for cash-burn drivers, year-end liabilities, deferred license revenue and any subsequent financing or clinical developments.
- Check final Quilience Phase 2 results and FDA/EMA feedback against the preliminary March 2022 interim data before relying on the proposed Phase 3 timetable.
- Track remediation and testing of the disclosed material weaknesses in financial reporting controls.